QGEN vs. RGEN, PCVX, TECH, EXEL, NBIX, RVMD, IBRX, HALO, CRSP, and KRYS
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Repligen (RGEN), Vaxcyte (PCVX), Bio-Techne (TECH), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Revolution Medicines (RVMD), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.
Repligen has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
Qiagen has a net margin of 17.38% compared to Qiagen's net margin of 2.44%. Repligen's return on equity of 12.59% beat Qiagen's return on equity.
Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Repligen received 156 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.08% of users gave Repligen an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Repligen presently has a consensus target price of $197.75, suggesting a potential upside of 15.01%. Qiagen has a consensus target price of $50.95, suggesting a potential upside of 11.50%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Repligen is more favorable than Qiagen.
97.6% of Repligen shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 1.2% of Repligen shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Qiagen had 3 more articles in the media than Repligen. MarketBeat recorded 7 mentions for Qiagen and 4 mentions for Repligen. Qiagen's average media sentiment score of 1.24 beat Repligen's score of 0.72 indicating that Repligen is being referred to more favorably in the media.
Summary
Repligen beats Qiagen on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
